Show simple item record

dc.contributor.authorNeoptolemos, J
dc.contributor.authorPalmer, D
dc.contributor.authorGhaneh, P
dc.contributor.authorPsarelli, E
dc.contributor.authorValle, Juan W
dc.contributor.authorHalloran, C
dc.contributor.authorFaluyi, O
dc.contributor.authorO'Reilly, D
dc.contributor.authorCunningham, D
dc.contributor.authorWadsley, J
dc.contributor.authorDarby, S
dc.contributor.authorMeyer, T
dc.contributor.authorGillmore, R
dc.contributor.authorAnthoney, A
dc.contributor.authorLind, P
dc.contributor.authorGlimelius, B
dc.contributor.authorFalk, S
dc.contributor.authorIzbicki, J
dc.contributor.authorMiddleton, G
dc.contributor.authorCummins, S
dc.contributor.authorRoss, P
dc.contributor.authorWasan, H
dc.contributor.authorMcDonald, A
dc.contributor.authorCrosby, T
dc.contributor.authorMa, Y
dc.contributor.authorPatel, K
dc.contributor.authorSherriff, D
dc.contributor.authorSoomal, R
dc.contributor.authorBorg, D
dc.contributor.authorSothi, S
dc.contributor.authorHammel, P
dc.contributor.authorHackert, T
dc.contributor.authorJackson, R
dc.contributor.authorBüchler, M
dc.date.accessioned2017-03-04T18:41:56Z
dc.date.available2017-03-04T18:41:56Z
dc.date.issued2017-01-24
dc.identifier.citationComparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. 2017, Lanceten
dc.identifier.issn1474-547X
dc.identifier.pmid28129987
dc.identifier.doi10.1016/S0140-6736(16)32409-6
dc.identifier.urihttp://hdl.handle.net/10541/620170
dc.description.abstractThe ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcitabine and capecitabine than with gemcitabine alone in advanced or metastatic pancreatic cancer. We aimed to determine the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer.
dc.language.isoenen
dc.rightsArchived with thanks to Lancet (London, England)en
dc.titleComparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.en
dc.typeArticleen
dc.contributor.departmentUniversity of Liverpool, Liverpool, UKen
dc.identifier.journalLanceten
refterms.dateFOA2018-12-17T14:48:39Z
html.description.abstractThe ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcitabine and capecitabine than with gemcitabine alone in advanced or metastatic pancreatic cancer. We aimed to determine the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer.


Files in this item

Thumbnail
Name:
PIIS0140673616324096.pdf
Size:
485.0Kb
Format:
PDF
Description:
Full text, Open Access Article

This item appears in the following Collection(s)

Show simple item record